Martin CannonPresident and CEO
Mr. Cannon has served as President, CEO and board member of New Health Sciences since 2004. Prior to joining NHSi, Mr. Cannon held senior positions with several leading management consulting firms including 15 years at Bain & Company and A.T. Kearney, which in 1997 acquired Cannon Associates, an international consulting and business development firm founded by Mr. Cannon. As a partner at Bain & Company and with his firm Cannon Associates, Mr. Cannon consulted extensively on growth and innovation strategies in a variety of industries including diagnostic instrumentation, blood banking and hospital management. Mr. Cannon also served as Executive Vice President with Commerce One, Inc., and Group President, Management Consulting with AppNet, Inc. where he was responsible for the development and deployment of software-based decision support platforms. He has served as a Board Member of the National Symphony Orchestra, The Washington Chorus and The US Russia Business Council. He is a graduate of Oxford University.
Michael BavoneseVice President, Finance and Administration
Mr. Bavonese joined the company in 2010 and is responsible for all administrative functions for the Company including finance, accounting, human resources, contracting, and investor relations. He also serves as Corporate Secretary. Prior to joining NHSi, he enjoyed a successful 14-year career with Johnson & Johnson where he served in various Corporate Finance roles of increasing scope and responsibility. During this period, Mr. Bavonese made particularly strong contributions in financial system design and implementation, financial planning and analysis and process improvements. He also prides himself in fostering relationships with executives, key stakeholders and staff while driving operational improvements and cost savings. He holds a B.S. in Finance from Drexel University, an M.B.A. from Syracuse University and is a Certified Management Accountant.
Rafael CorderoVice President, Product Development
Rafael Cordero has over 25 years of experience in risk managed medical device and system design in both large and small organizations. He has shown continued success through design management integration to lead teams to project completion with emphasis on the user experience and patient outcomes. He has a proven track record of transitioning advanced development output into product development for rapid kickstart to the concept and pre-clinical phases. At Aspect Medical, he successfully led the design integration of the Disposable line of products for the BIS Level of Consciousness Monitoring for Anesthesia Management. At Covidien’s RMS Division, he evolved the group into a Center of Excellence of Disposables and Sensor Technology, including pulse oximetry. Mr. Cordero was VP of Cathether R&D at CSA Medical Inc prior to joining the NHSi team in August of 2014, He is a graduate of Boston University.
Andrew DunhamChief Scientific Officer
Dr. Dunham serves as Vice President of Research and Clinical Affairs since January 2015. Prior to joining NHSi, Dr. Dunham held researcher and senior positions at both specialty chemical and healthcare companies including 14 years at Baxter Healthcare. His experience at Baxter included leading the corporate R&D group comprising the global centers for Sterility Assurance, Particle & Imaging, Human Factors & Industrial Design, Pre-clinical, Toxicology, and Histology, Biochemistry and Cell Biology, Organic Synthesis and Analytical Chemistry, Advanced Engineering and Prototyping, and Stability Operations teams. Dr. Dunham has extensive experience applying this broad range of technologies across a diverse range of pharmaceutical and medical device products from development through product support. He is a graduate of the Northern Illinois University, the University of Colorado at Boulder, and had post-doctoral research experience at the University of Colorado Health Sciences Center School of Pharmacy.
Tony PareChief Commercial Officer
Tony has 30+ years experience in general management and business development, with a track record of executing large scale, value creation strategies and improving profitability. Recently, Tony was the VP of Business Development, Mergers and Acquisitions for Haemonetics Corporation. In this role, Tony was responsible for all inorganic growth activity, as well as strategy development for entering into new markets. Tony led the acquisition and integration of 13 companies that represented over $300M of the $930M in corporate revenues. In a prior role, Tony started and led the blood software franchise as its President and General Manager, and grew it to $70M in revenues. Tony holds a B.S. in Engineering from Maine Maritime Academy and a Masters in Engineering Administration from George Washington University.
Tatsuro Yoshida, PhDDirector, R&D
Dr. Yoshida serves as Director, Research and Development for Hemanext and is one of the two co-inventors of the Hemanext technology. He specializes in red blood cell physiology and heme protein biochemistry. Prior to joining New Health Sciences, Dr. Yoshida was Senior Research Associate at Boston University’s Department of Biomechanical Engineering. He also worked at Los Alamos National Laboratory where he began development of the anaerobic blood storage technology. Dr. Yoshida earned a Ph.D. in Biophysics from the University of Michigan, and a B.A. in Physics and Biophysics from the University of Pennsylvania.